Post Herpetic Neuralgia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Afr

Post Herpetic Neuralgia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Post herpetic neuralgia (PHN) is characterized by moderate to severe nerve pain resulting from damage to a peripheral nerve due to the reactivation of the varicella zoster virus (shingles). PHN is nerve pain that persists for more than 30 days after the reactivation of herpes zoster.The global post herpetic neuralgia treatment market is predominantly driven by key players, including Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., and Endo Pharmaceuticals Inc., who collectively account for more than 50% of the market's revenue. These leading manufacturers are capitalizing on growing awareness about post herpetic neuralgia treatment and the increasing geriatric population.

Market Consolidation and Challenges

While large vendors dominate the post herpetic neuralgia treatment market, consolidation hasn't necessarily translated into increased profitability due to patent expirations and the effectiveness and efficiency challenges associated with treatment options. However, the market's dynamics are evolving as awareness about post herpetic neuralgia treatment grows, especially among the elderly.

Drivers of Market Growth

The global post herpetic neuralgia treatment market is experiencing growth due to the rising prevalence of post herpetic neuralgia and the expanding geriatric population. Furthermore, the development of healthcare infrastructure globally, coupled with government support for post herpetic neuralgia treatment products, is expected to drive market growth.

Growing Geriatric Population and Screening Rates

The increasing rates of screening and the growth in the geriatric population are critical drivers of the post herpetic neuralgia treatment market. According to the Center for Disease Control and Prevention, shingles is on the rise among adults in the United States, with approximately 1 in 3 people developing shingles in their lifetime. A significant percentage of shingles cases result in post herpetic neuralgia, particularly in individuals aged 50 and older.

Concerns Over Opioid Use

Despite the market's potential, concerns over opioid use and the rising mortality rates due to overdoses pose significant constraints on the post herpetic neuralgia treatment market. Opioid overdose deaths, accounting for a substantial portion of drug overdose fatalities, have raised concerns over treatment options.

Opportunities in New Drug Development

The development of new drugs presents a significant opportunity in the post herpetic neuralgia treatment market, as a definitive curative treatment is yet to be discovered. Government support for post herpetic neuralgia treatment products, particularly through initiatives and investments in research and development, is expected to foster market growth.

Regional Variations in Market Growth

In developed regions like North America and Europe, the presence of a larger economy, higher purchasing power, and extensive healthcare infrastructure support the growth of the post herpetic neuralgia treatment market. The U.S., in particular, stands out due to excellent reimbursement policies and increasing incidence rates of post herpetic neuralgia. In Asia Pacific, Japan, India, Australia, and New Zealand are key players in the market.

Challenges to Market Realization

Despite the market's potential, challenges remain, particularly related to the efficacy and efficiency of treatment options. While calcium-channel blockers, tricyclic antidepressants, steroids, and opioids are used in post herpetic neuralgia treatment, they have limitations and side effects that restrict their widespread use.

Competitive Analysis

The post herpetic neuralgia treatment market features key players such as Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Endo Pharmaceuticals Inc., and others. These players are profiled in the competition section of the report, outlining their market shares, strategies, product offerings, marketing approaches, and company dashboards.

Post Herpetic Neuralgia Treatment Market Segmentation:

The report presents a detailed segmentation of the post-herpetic neuralgia treatment market based on treatment type, distribution channels, and region. The treatment types include drugs, patches, and steroid injectables. Within the drug segment, further subdivisions are made for anticonvulsants, antidepressants, and opioids.

Under the patches segment, there are subdivisions for lidocaine skin patches and capsaicin skin patches. Distribution channels comprise institutional sales, which encompass hospital pharmacies and clinics, and retail sales, which include retail pharmacies, drug stores, and mail-order pharmacies.

The post-herpetic neuralgia treatment market analysis covers regions including North America, Latin America, Europe, Asia Pacific excluding China, China, and the Middle East and Africa.

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.